DarioHealthDRIO
DRIO
About: DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Employees: 252
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,850% more call options, than puts
Call options by funds: $117K | Put options by funds: $6K
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
8.99% less ownership
Funds ownership: 35.71% [Q2] → 26.72% (-8.99%) [Q3]
15% less funds holding
Funds holding: 39 [Q2] → 33 (-6) [Q3]
29% less capital invested
Capital invested by funds: $12.7M [Q2] → $8.98M (-$3.74M) [Q3]
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for DRIO.
Financial journalist opinion
Based on 3 articles about DRIO published over the past 30 days
Neutral
PRNewsWire
15 hours ago
DarioHealth Announces $25.6M Private Placement Positioning the Company to Execute on Strategy Aiming to Reach Operational Cash Flow Positive Run Rate by the End of 2025
Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategy Financing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channels NEW YORK , Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the successful closing of a $25.6 million private placement of convertible preferred stock, priced in accordance with Nasdaq market rules. The majority of the funds were secured from existing shareholders, with the remainder contributed by a network of leading accredited healthcare investors and executives from the healthcare sector.
Neutral
Business Wire
1 week ago
DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market
NEW YORK--(BUSINESS WIRE)--Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The company's latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Dario's shar.
Neutral
PRNewsWire
1 week ago
DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets
New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK , Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a collaboration with MediOrbis, a multi-specialty digital health provider, to add prescribing capabilities to Dario's GLP-1 behavior change solution for a comprehensive medical weight loss program. This strategic addition creates a fully integrated solution for employers covering weight-loss medications and supports direct-to-consumer offerings, expanding Dario's addressable market in one of the fastest-growing segments of digital health.
Neutral
PRNewsWire
2 months ago
Dario Signs Four New Employer Contracts Across Full Product Suite
Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK , Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025. Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025.
Neutral
Seeking Alpha
2 months ago
DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2024 Results Call. [Operator Instructions] This call is being recorded on November 7, 2024.
Negative
Zacks Investment Research
2 months ago
DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.49 per share a year ago.
Neutral
PRNewsWire
2 months ago
DarioHealth Reports Third Quarter 2024 Financial and Operating Results
Demonstrated strong improvements in financial performance and business momentum. Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.
Neutral
PRNewsWire
2 months ago
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement
The new platform services subscription contract with a top six U.S. pharma client marks a pivotal shift in Dario's pharma channel, transitioning the business model from milestone-based to recurring service subscription fees by expanding engagement with payors and pharmacy benefit managers (PBMs) NEW YORK , Nov. 4, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new collaboration with a pharma company that will utilize Dario Connect (formerly Twill Care) among their patient populations to further their direct-to-consumer efforts using Dario's refined engagement and navigation technologies. In an effort to strengthen and expand connections across patient populations that are candidates for a new drug to treat psoriasis, a top pharmaceutical company chose Dario to pilot a cutting-edge initiative aimed to help onboard patients that will engage with the drug via the platform.
Neutral
PRNewsWire
2 months ago
Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population
The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK , Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions.
Neutral
PRNewsWire
2 months ago
DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th
Company to host conference call and webcast at 8:30am ET NEW YORK , Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.
Charts implemented using Lightweight Charts™